Medtronic plc
MDT- Exchange
- NYSE
- Industry
- Electromedical & Electrotherapeutic Apparatus
- SEC CIK
- 0001613103
In the last 90 days, Medtronic plc insiders filed 0 open-market purchases and 3 sales; 2,151 institutions reported holding it in 13F filings for Q2 2026, worth $86.8B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:42 PM ET
Revenue flow, Q1 FY2027
Where the revenue went in Q1 FY2027, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one quarter, newest first.
| Line item | Q1 FY2027 | Q4 FY2026† | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025† | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|---|---|---|---|
| Period end | Jul 31, 2026 | Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 |
| Filing | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Reported | Sep 1, 2026 | Jun 3, 2026 | Feb 17, 2026 | Nov 18, 2025 | Aug 19, 2025 | May 21, 2025 | Feb 18, 2025 | Nov 19, 2024 |
| Revenue | $9.76B | $9.81B† | $9.02B | $8.96B | $8.58B | $8.93B† | $8.29B | $8.40B |
| Cost of revenue | $3.42B | $3.40B† | $3.26B | $3.06B | $3.00B | $3.15B† | $2.78B | $2.95B |
| Research and development | $771.0M | $671.0M† | $722.0M | $754.0M | $726.0M | $684.0M† | $675.0M | $697.0M |
| Selling, general and administrative | $3.20B | $3.06B† | $2.96B | $2.96B | $2.81B | $2.72B† | $2.72B | $2.76B |
| Operating income | $1.76B | $1.87B† | $1.46B | $1.69B | $1.45B | $1.44B† | $1.65B | $1.59B |
| Income tax | $289.0M | $575.0M† | $254.0M | $215.0M | $255.0M | $199.0M† | $237.0M | $281.0M |
| Net income | $1.47B | $1.24B† | $1.14B | $1.37B | $1.04B | $1.06B† | $1.29B | $1.27B |
| EPS, basic | $1.15 | – | $0.89 | $1.07 | $0.81 | – | $1.01 | $0.99 |
| EPS, diluted | $1.14 | – | $0.89 | $1.07 | $0.81 | – | $1.01 | $0.99 |
| Weighted shares, basic | 1.28B | – | 1.28B | 1.28B | 1.28B | – | 1.28B | 1.28B |
| Weighted shares, diluted | 1.29B | – | 1.29B | 1.29B | 1.29B | – | 1.29B | 1.29B |
| Margins and growth | ||||||||
| Operating margin | 18.1% | 19.1% | 16.2% | 18.8% | 16.8% | 16.1% | 19.9% | 19.0% |
| Net margin | 15.1% | 12.7% | 12.7% | 15.3% | 12.1% | 11.8% | 15.6% | 15.1% |
| Revenue growth, year over year | +13.7% | +9.9% | +8.7% | +6.6% | +8.4% | +3.9% | +2.5% | +5.2% |
| Net income growth, year over year | +41.3% | +17.8% | −11.7% | +8.2% | −0.2% | +61.5% | −2.1% | +39.7% |
Balance sheet
Each column is one quarter, newest first.
| Line item | Q1 FY2027 | Q4 FY2026† | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025† | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|---|---|---|---|
| Period end | Jul 31, 2026 | Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 |
| Filing | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Reported | Sep 1, 2026 | Jun 3, 2026 | Feb 17, 2026 | Nov 18, 2025 | Aug 19, 2025 | May 21, 2025 | Feb 18, 2025 | Nov 19, 2024 |
| Cash and equivalents | $1.69B | $1.95B | $1.15B | $1.28B | $1.27B | $2.22B | $1.24B | $1.39B |
| Short-term investments | $7.13B | $7.27B | $7.24B | $7.04B | $6.85B | $6.75B | $6.68B | $6.59B |
| Accounts receivable | $6.36B | $6.64B | $6.36B | $6.39B | $6.26B | $6.51B | $6.12B | $6.26B |
| Inventory | $6.21B | $5.95B | $6.31B | $6.16B | $5.89B | $5.48B | $5.61B | $5.48B |
| Total current assets | $24.4B | $24.8B | $24.1B | $24.0B | $23.2B | $23.8B | $22.5B | $22.4B |
| Property, plant and equipment | $7.47B | $7.42B | $7.18B | $7.16B | $7.01B | $6.84B | $6.59B | $6.44B |
| Goodwill | $43.2B | $42.6B | $41.9B | $41.8B | $42.0B | $41.7B | $40.8B | $41.2B |
| Intangible assets | $10.2B | $10.1B | $10.3B | $10.8B | $11.2B | $11.7B | $12.2B | $12.4B |
| Total assets | $93.3B | $93.0B | $91.5B | $91.3B | $91.0B | $91.7B | $90.0B | $90.0B |
| Accounts payable | $2.69B | $2.64B | $2.57B | $2.58B | $2.56B | $2.45B | $2.29B | $2.38B |
| Short-term debt | $2.54B | $1.79B | $191.0M | $1.42B | $2.43B | $2.87B | $2.62B | $3.72B |
| Total current liabilities | $11.8B | $11.7B | $9.49B | $9.94B | $11.5B | $12.9B | $11.8B | $12.2B |
| Total liabilities | $42.5B | $43.0B | $42.3B | $42.5B | $42.8B | $43.4B | $40.4B | $41.3B |
| Shareholders' equity | $50.9B | $50.1B | $49.2B | $48.9B | $48.1B | $48.3B | $49.6B | $48.7B |
Cash flow statement
Each column is one quarter, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | Q1 FY2027 | Q4 FY2026† | Q3 FY2026† | Q2 FY2026† | Q1 FY2026 | Q4 FY2025† | Q3 FY2025† | Q2 FY2025† |
|---|---|---|---|---|---|---|---|---|
| Period end | Jul 31, 2026 | Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 |
| Filing | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Reported | Sep 1, 2026 | Jun 3, 2026 | Feb 17, 2026 | Nov 18, 2025 | Aug 19, 2025 | May 21, 2025 | Feb 18, 2025 | Nov 19, 2024 |
| Operating cash flow | $1.79B | $2.57B† | $2.74B† | $925.0M† | $1.09B | $2.53B† | $2.57B† | $958.0M† |
| Capital expenditures | $503.0M | $488.0M† | $444.0M† | $468.0M† | $504.0M | $459.0M† | $476.0M† | $404.0M† |
| Free cash flow | $1.29B | $2.08B | $2.30B | $457.0M | $584.0M | $2.07B | $2.10B | $554.0M |
| Depreciation and amortization | $729.0M | $716.0M† | $749.0M† | $745.0M† | $748.0M | $840.0M† | $684.0M† | $675.0M† |
| Stock-based compensation | $125.0M | $95.0M† | $94.0M† | $182.0M† | $86.0M | $89.0M† | $98.0M† | $159.0M† |
| Dividends paid | $921.0M | $908.0M† | $911.0M† | $910.0M† | $910.0M | $897.0M† | $897.0M† | $897.0M† |
| Share buybacks | $267.0M | $435.0M† | $105.0M† | $372.0M† | $123.0M | $274.0M† | $181.0M† | $288.0M† |
| Investing cash flow | -$1.62B | -$917.0M† | -$816.0M† | -$482.0M† | -$719.0M | -$490.0M† | -$843.0M† | -$345.0M† |
| Financing cash flow | -$343.0M | -$888.0M† | -$2.09B† | -$395.0M† | -$1.38B | -$1.34B† | -$1.75B† | -$534.0M† |
| Net change in cash | -$258.0M | $803.0M† | -$136.0M† | $9.00M† | -$945.0M | $978.0M† | -$154.0M† | $83.0M† |
| Ratio | ||||||||
| Stock-based compensation, % of revenue | 1.3% | 1.0% | 1.0% | 2.0% | 1.0% | 1.0% | 1.2% | 1.9% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- Values marked † are derived: Q4 is the full year minus the first three quarters, single-quarter cash flows are year-to-date figures minus the previous year-to-date figures, and the Q4 balance sheet is the year-end balance sheet.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.